Want to see HK:8049 full AI Analyst Report?
8049 Stock Chart & Stats
HK$2.16
-HK$0.03(-2.08%)
At close: 4:00 PM EST
HK$2.16
-HK$0.03(-2.08%)
Day’s Range― - ―
52-Week RangeHK$1.82 - HK$3.00
Previous CloseN/A
Volume24.00K
Average Volume (3M)39.80K
Market Cap
HK$1.33B
Enterprise ValueHK$245.91
Total Cash (Recent Filing)HK$902.41M
Total Debt (Recent Filing)HK$399.93K
Price to Earnings (P/E)4.0
Beta0.37
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield11.31%
Share Statistics
EPS (TTM)0.50
Shares Outstanding172,500,000
10 Day Avg. Volume2,800
30 Day Avg. Volume39,800
Financial Highlights & Ratios
PEG Ratio0.92
Price to Book (P/B)0.65
Price to Sales (P/S)1.22
P/FCF Ratio3.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and a growing equity base provide financial resilience and preserve flexibility for investment, operations, or downturn protection. This conservative capital structure reduces balance-sheet strain and supports stability over the next several quarters.
Strong Cash GenerationCash conversion that broadly tracks earnings indicates that reported profitability is supported by cash generation rather than only accounting results. The strong 2025 free-cash-flow outcome can fund operations, investment, and shareholder returns while limiting financing dependence.
Resilient ProfitabilityConsistently high gross and net margins demonstrate an established ability to retain profit from revenue and maintain operating discipline. Stable profitability provides a durable earnings base, even as the company faces slower top-line expansion.
Bears Say
Cooling Revenue MomentumThe shift from earlier strong expansion to flat, modest, and then slightly negative revenue growth signals weaker top-line momentum. If sustained, slower growth could limit operating leverage, reduce reinvestment opportunities, and temper future earnings expansion.
Volatile Free Cash FlowAlthough recent cash generation is strong, the history shows meaningful year-to-year variability in free cash flow and cash conversion. Such fluctuations can make internally funded planning less predictable and may complicate the timing of investment or distributions.
Recent Debt IncreaseThe increase in debt introduces a developing balance-sheet watch point despite still-manageable leverage. If borrowing continues rising while revenue momentum remains weak, financial flexibility could narrow and more cash flow may be directed toward debt servicing.
8049 FAQ
What was Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s price range in the past 12 months?
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H lowest stock price was HK$1.82 and its highest was HK$3.00 in the past 12 months.
What is Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s market cap?
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s market cap is HK$1.33B.
When is Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s upcoming earnings report date?
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s upcoming earnings report date is Apr 01, 2027 which is in 193 days.
How were Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s earnings last quarter?
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H released its earnings results on Aug 14, 2026. The company reported HK$0.25 earnings per share for the quarter.
Is Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H overvalued?
According to Wall Street analysts Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s price is currently Overvalued.
Does Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H pay dividends?
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H pays a Notavailable dividend of HK$0.287 which represents an annual dividend yield of 11.31%. See more information on Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H dividends here
What is Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s EPS estimate?
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H have?
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H has 172,500,000 shares outstanding.
What happened to Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s price movement after its last earnings report?
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H reported an EPS of HK$0.25 in its last earnings report. Following the earnings report the stock price went down -3.664%.
Which hedge fund is a major shareholder of Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:8049
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H
Jilin Province Huinan Changlong Bio-pharmacy Company Limited focuses on the manufacturing and sale of traditional Chinese medicines and various pharmaceutical products within the People's Republic of China. The company's extensive product portfolio includes a wide range of dosage forms such as tablets, capsules, and pills, as well as specialized items like Chinese medicine pretreatment and extraction products. They also provide various injectable solutions, including powders for injection, lyophilized powders for injection, and small volume liquid injections, along with active pharmaceutical ingredients (APIs) and granules. These products are primarily sold under the "Changlong" and "Qing Tong" brand names. Established in 1989, and headquartered in Kowloon, Hong Kong, the company was previously known as Jilin Province Huinan Biochemical Pharmaceutical Company Limited.
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H (8049) Earnings & Revenues
Technical Analysis
Essex Bio-Technology
―
JBM (Healthcare) Ltd.
―
Dawnrays Pharmaceutical Holdings Ltd.
―
Jacobson Pharma Corporation Limited
―
VISEN Pharmaceuticals
―